Browsing: Novo

By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN(Reuters) -Novo Nordisk said on Friday its experimental next-generation obesity drug CagriSema helped patients…

By Suzanne McGee (Reuters) – Three separate asset management firms launched exchange-traded funds on Tuesday, unveiling products focused on securitized…

By Chad Terhune (Reuters) – U.S. government health plans account for the lion’s share of coverage for popular new weight-loss…

Investing.com — Novo Nordisk (CSE:) has been placed on JPMorgan’s Catalyst Watch list, signaling heightened anticipation as the company approaches…

By Jody Godoy and Maggie Fick NEW YORK (Reuters) – Five U.S. consumer groups and two large labor unions urged…

Investing.com — Bank of America (BofA) adjusted its price objective for Novo Nordisk (NYSE:) shares to DKK1075 from the previous…

By Maggie Fick and Patrick Wingrove LONDON/NEW YORK (Reuters) – As Eli Lilly (NYSE:)’s weight-loss drug Zepbound gains ground in…

By Ahmed Aboulenein WASHINGTON (Reuters) -Senator Bernie Sanders on Wednesday expressed confidence that Novo Nordisk (NYSE:) can be convinced to…

LONDON (Reuters) – Shares in Novo Nordisk (NYSE:), maker of the wildly popular obesity drug Wegovy, were down 1.9% on…

Novo Nordisk investors appeared unperturbed Thursday by a critical Harvard report that linked weight loss drugs to a rare eye…